Next Article in Journal
Microglial Phenotypes and Their Relationship to the Cannabinoid System: Therapeutic Implications for Parkinson’s Disease
Next Article in Special Issue
Introduction of Mercaptoethyl at Sorafenib Pyridine-2-Amide Motif as a Potentially Effective Chain to Further get Sorafenib-PEG-DGL
Previous Article in Journal
Proteomic Analysis of Saccharomyces cerevisiae Response to Oxidative Stress Mediated by Cocoa Polyphenols Extract
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 25
Issue 3
10.3390/molecules25030450
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Synthesis of a New Series of Nitrogen/Sulfur Heterocycles by Linking Four Rings: Indole; 1,2,4-Triazole; Pyridazine; and Quinoxaline

by
Ahmed T. A. Boraei
1,*,
Ahmed A. M. Sarhan
2,
Sammer Yousuf
3 and
Assem Barakat
4,5,*
1
Chemistry Department, Faculty of Science, Suez Canal University, Ismailia 41522, Egypt
2
Chemistry Department, Faculty of Science, Arish University, Al-Arish 45511, Egypt
3
H.E.J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Karachi 75270, Pakistan
4
Chemistry Department, College of Science, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia
5
Chemistry Department, Faculty of Science, Alexandria University, P.O. Box 426, Ibrahimia, Alexandria 21321, Egypt
*
Authors to whom correspondence should be addressed.
Molecules 2020, 25(3), 450; https://doi.org/10.3390/molecules25030450
Submission received: 17 December 2019 / Revised: 14 January 2020 / Accepted: 17 January 2020 / Published: 21 January 2020
(This article belongs to the Special Issue Synthetic Heterocyclic Chemistry)
Browse Figures
Versions Notes

Abstract

:
A new series of nitrogen and sulfur heterocyclic systems were efficiently synthesized by linking the following four rings: indole; 1,2,4-triazole; pyridazine; and quinoxaline hybrids. The strength of the acid that catalyzes the condensation of 4-amino-5-(1H-indol-2-yl)-2,4-dihydro-3H-1,2,4-triazole-3-thione 1 with aromatic aldehydes controlled the final product. Reflux in glacial acetic acid yielded Schiff bases 2–6, whereas concentrated HCl in ethanol resulted in a cyclization product at C-3 of the indole ring to create indolo-triazolo-pyridazinethiones 7–16. This fascinating cyclization approach was applicable with a wide range of aromatic aldehydes to create the target cyclized compounds in excellent yield. Additionally, the coupling of the new indolo-triazolo-pyridazinethiones 7–13 with 2,3-bis(bromomethyl)quinoxaline, as a linker in acetone and K2CO3, yielded 2,3-bis((5,6-dihydro-14H-indolo[2,3-d]-6-aryl-[1,2,4-triazolo][4,3-b]pyridazin-3 ylsulfanyl)methyl)quinoxalines 19–25 in a high yield. The formation of this new class of heterocyclic compounds in high yields warrants their use for further research. The new compounds were characterized using nuclear magnetic resonance (NMR) and mass spectral analysis. Compound 6 was further confirmed by the single crystal X-ray diffraction technique.

Graphical Abstract

1. Introduction

Nitrogen-, oxygen-, and sulfur-containing heterocycles are one of the most important compounds found in organic chemistry, as well as in the pharmaceutical industry [1,2,3,4,5,6]. Among these, 4-amino-1,2,4-triazole-3-thione-based indole scaffolds have drawn considerable attention in the chemical community, including in material science and agrochemical applications. The substituted triazoles have emerged in different pharmaceutical applications including antiproliferative [7], antiviral [8], antimalarial [9], antimicrobial [10], and anticonvulsant agents [11]. Additionally, a few studies have reported their use as inhibitors for metalloenzyme-including ureases [12], dizinc metallo-β-lactamase [13], the tumor necrosis factor alpha (TNF-α) converting enzyme [14], ADAM metallopeptidase with thrombospondin type 1 motif 5 (ADAMTS-5) [15], dicopper dopamine-β-hydroxylase inhibitors [16], and also as human carbonic anhydrase enzyme and acetylcholinesterase (AChE) activities [17].
Many triazole-based indoles as a core structure are reported with pharmaceutical targets. Westwell, A.D. et al., independently introduced the synthesis of a set of compounds with a 4-amino-1,2,4-triazole-3-thione-based indole moiety via S-arylation; among these series, they discovered that 3-nitrobenzyl derivative has higher activity in Bc1-2-expressing human cancer cell lines at the BH3 binding pocket with (IC50 μM) equal to 0.31 ± 0.03 μM for breast (MDA-MB-231), 0.40 ± 0.07 μM for cervical (HeLa), and 0.65 ± 0.21 μM for human leukemia (KG1a), respectively [18]. Another analogue derived from triazole-based indole was reported also by Westwell, A.D. et al., which exhibited anticancer activity against breast MDA-MB-231 and cervical HeLa cell lines; IC50 = 0.91 ± 0.21 μM, and 0.25 ± 0.11 µM, respectively [19]. In the same area of research, Boraei, A.T.A. et al. explored a set series of compounds including the S-benzylation of a triazole-based indole. Additionally, another set of triazolo-thiadiazepine and triazolo-thiadiazine scaffolds were discovered as potential inhibitors for epidermal growth factor receptor (EGFR) [20,21] (Figure 1).
A novel fluorophore was derived from a triazole–indole scaffold for a fluorimetric DNA biosensor technique, which was applied for tumor suppressor gene detection and was achieved by Darestani-Farahani, M. et al., in 2018 [22]. Indeed, the indole–triazole Schiff base was synthesized and used as a fluorescent probe for Al3+ ions [23]. This research area reported in the literature regarding indole–triazole hybrids has gained attention from a large number of organic chemists, as well as medicinal chemists.
4-Amino-1,2,4-triazole-3-thione-based indole scaffolds have been used in a large number of organic transformations [24,25], including in metal complexation and in applications for conventional Mizoroki–Heck, and Tsuji–Trost reaction catalysis [26]. Triazole–indole hybrids are commonly reported as synthetic intermediates with hydrazonoyl halides for the synthesis of annulation heterocycles [27]. Gomha, S.M. and Riyadh, S.M. independently applied the microwave technique for the synthesis of a set of compounds with triazole–indole–thiadiazole moieties starting from 4-amino-1,2,4-triazole-3-thione-based indole as a building block, and they explored their potential antimicrobial activity [28]. We have noticed, in the specific reaction of triazole–indole as a core structure with aldehydes, that carbon position number 2 in the indole scaffold plays a crucial rule in chemical transformation [29,30]. Furthermore, novel triazole–indole–oxadiazole compounds were synthesized utilizing triazole–indole hit via ultrasound irradiation, and the synthesized compounds exhibited antimicrobial activity against E. coli and S. aureus with values of (MIC) between 2 and 8 mg/mL [31]. One more example derived from an indolo–trizolo scaffold was reported by Diana, P. et al., which showed remarkable antibiofilm activity against S. aureus [32]. The quinoxaline scaffold showed interesting biological activity [33]. Diana, P. et al., synthesized a new series of aza-isoindolo and isoindolo-azaquinoxaline derivatives which have been discovered to be anticancer agents [34,35].
With these findings mentioned above, here, we reported the synthesis of new multi-nitrogen/sulfur heterocyclic systems by linking the following four rings: Indole; 1,2,4-triazole; pyridazine; and quinoxaline.

2. Results and Discussion

2.1. Synthesis of 2–16 and 19–25

The condensation of 4-amino-5-(1H-indol-2-yl)-2,4-dihydro-3H-1,2,4-triazole-3-thione 1 with benzaldehyde, 4-fluorobenzaldehyde, 3-bromobenzaldehyde, p-tolualdehyde, and o-vanillin in glacial acetic acid yielded the Schiff bases 2–6 in low yield. Alternatively, we carried out the reaction using a stronger acidic medium of concentrated HCl in ethanol under a reflux condition. Surprisingly, this reaction condition exclusively yielded the cyclized compounds indolo-triazolo-pyridazinethiones 7–16 in excellent yields. The approach was further extended for the substrate scope, and the reaction was performed with ten aromatic aldehydes with different electronic effects: benzaldehyde, 4-fluorobenzaldehyde, 3-bromobenzaldehyde, p-tolualdehyde, 2,3,4-trimethoxybenzaldehyde, 4-chlorobenzaldehyde, 4-bromobenzaldehyde, 3,4-dihydroxybenzaldehyde, 4-hydroxy-3-methoxybenzaldehyde, and 2-hydroxy-3-methoxybenzaldehyde (Scheme 1). Compounds 17 and 18 did not occur under the reaction condition.
The coupling of indolo-triazolo-pyridazinethiones 7–13 with 2,3-bis(bromomethyl)quinoxaline in acetone and K2CO3 yielded 2,3-bis((5,6-dihydro-14H-indolo[2,3-d]-6-aryl-[1,2,4-triazolo][4,3-b]pyridazin-3-ylsulfanyl)methyl)quinoxalines 19–25 in excellent yields (Scheme 2).

2.2. Structural Assignments

The structural assignments were established based on 1H- and 13C-NMR, and the differentiation between the two isomers 2 and 7 is discussed by comparing their spectra in Figure 2.
The Schiff base structures 2–6 were assigned from their spectra, which showed the following: The aromatic protons appeared in the range from 7.01 to 8.03 ppm, the benzylidene CH proton appeared as singlet around 9.73 ppm, and two D2O exchangeable signals were assigned for indole NH near 11.90 ppm, and the second for triazole NH that found around 14.30 ppm. The 13C-NMR showed only aromatic and thiocarbonyl signals (C=S) between 105.0 and 167.0 ppm (Figure 2A,B). There was exclusive formation of indolo-triazolo-pyridazinethiones 7–16 whereas, indolo-triazolo-thiadiazole 17 and indolo-triazolo-triazine 18 did not occur. The structures assignments were deduced from the 1H-NMR, which showed the appearance of pyridazine CH proton as a doublet around 5.92 ppm; then, the aromatic protons and three D2O exchangeable signals around 7.01, 12.24, and 13.64 ppm assigned for pyridazine NH, indole NH, and triazole NH protons, respectively, appeared. 13C-NMR displayed the pyridazine CH at 56.13 ppm and the thiocarbonyl signal (C=S) around 164.73 ppm (Figure 2C,D). In addition, the disappearance of one CH from the indole signals strongly implied the indolo-triazolo-pyridazinethiones 7–16 structures. Structure 17 was excluded because it should contain the indole CH and should not contain any thiocarbonyl signal. Structure 18 was also excluded because our structures contain the indole NH. The 1H-NMR of derivatives 19–25 displayed the methylene protons around 5.00 ppm, and the CH of the pyridazine ring was detected at 5.92 ppm. Moreover, two exchangeable protons were detected at 7.00 ppm for NH pyridazine and 12.36 ppm for the NH indole. 13C-NMR demonstrated the methylene carbons around 35.10 ppm, and no carbons were detected near to 160.00 ppm. The results support the idea that the alkylation of bis(bromomethyl)quinoxaline was performed with sulfur rather than nitrogen.

2.3. X-ray Diffraction Analysis of 6

The structure of 6 was determined by single crystal X-ray diffraction (Figure 3). Compound 6 crystallized in a triclinic system and P-1 space group with Z = 2 and two molecular formula per asymmetric unit (Table 1 and Table 2). For simplicity, one of the two-formula units with atom numbering is shown in Figure 3. The lists of the bond distances and angles are collected in Tables S1 and S2 (Supplementary data). The indole moiety is typically a planar system in which the plane passes through the triazole-3-thione, and the aryl moieties are twisted from the plane of the indole plane by 8.91° and 52.82°, respectively, for the molecular unit shown in Figure 4. The other molecular unit with higher atom numbering showed similar twists of 6.60° and 52.98°, respectively [36,37,38].
The structure showed two intramolecular hydrogen bonds of the type O-H…N between the hydroxyl group as a hydrogen bond donor, the adjacent Schiff base nitrogen atom as a hydrogen bond acceptor, and donor-acceptor distances in the range of 2.659(6)–2.664(6) Å (Table 3). In addition, each of the two units in the crystal are connected by weak C11-H11…S2 hydrogen bonds with a donor-acceptor distance of 3.391(5) Å, leading to the hydrogen-bonded dimeric units shown in Figure 4.

3. Materials and Methods

Melting points are determined using a melting-point apparatus (SMP10) in open capillaries and are uncorrected. The progress of the reactions was monitored by thin layer chromatography (Merck). Detections were achieved by UV light illumination. For flash chromatography, commercial silica was used. Nuclear magnetic resonance (1H-NMR, 13C-NMR, and 2D NMR) spectra were determined in DMSO-d6 and were recorded on Bruker AC 300/500 spectrometers using TMS as an internal standard. Chemical shifts are termed in δ (ppm) and coupling constants are described in Hz. The assignment of exchangeable OH and NH was confirmed by D2O. CHNS-microanalysis was done using a Flash EA-1112 instrument. The HREI mass spectra were detected using a Finnigan MAT 95XP. The FAB-MS was done using Jeol JMS HX110. The IR were detected using a Bruker Alpha ATR-FTIR.

3.1. Procedure for 2–6

The appropriate aldehyde (1.1 mmol) and 4-amino-5-(1H-indol-2-yl)-2,4-dihydro-3H-1,2,4-triazole-3-thione 1 (1.0 mmol) were refluxed in glacial acetic acid (5.0 mL) for 3 h, then cooled, crystals either appear during cooling then filtered and recrystallized from ethanol or the mixture was poured into cold water; the formed ppt was filtered, dried, and purified by silica-column chromatography using EA/H (1: 1) as an eluent.
4-(Benzylideneamino)-5-(1H-indol-2-yl)-2H-1,2,4-triazole-3(4H)-thione2. Yield 65%; m.p. 221 to 222 °C, 1H-NMR (DMSO-d6, 500 MHz) δ 7.03 (dd, 1 H, J 8.0, J 7.5 Hz), 7.08 (d, 1 H, J 1.0 Hz), 7.20 (dd, 1 H, J 7.5, J 8.2 Hz), 7.45 (d, 1 H, J 8.2 Hz), 7.61 to 7.70 (m, 4 H), 8.02 (d, 2 H, J 7.3 Hz), 9.73 (s, 1 H, CH=N), 11.89 (br. s, 1 H, NHIndole), 14.28 (br. s, H, NHTriazole); 13C-NMR (DMSO-d6, 125 MHz) δ 105.30, 111.88, 119.87, 121.25, 122.34, 123.69, 127.26, 128.87, 129.30, 131.90, 132.95, 136.93, 143.41, 162.09, 167.12; IR (cm−1): 1601, 2923, 3223, 3423; elemental analysis calculation for C17H13N5S: C, 63.93; H, 4.10; N, 21.93; S, 10.04 found: C, 63.63; H, 3.95; N, 21.99; S, 10.15.
(E)-4-(4-Flourobenzylideneamino)-5-(1H-indol-2-yl)-2H-1,2,4-triazole-3(4H)-thione3. Yield: 71%; m.p. 227 to 228 °C, 1H-NMR (DMSO-d6, 3400 MHz) δ 7.03 (ddd, 1 H, J 8.0, J 7.5, J 0.9 Hz), 7.09 (d, 1 H, J 1.03 Hz), 7.22 (ddd, 1H, J 7.5, J 8.2, J 1.1 Hz), 7.46 to 7.50 (3, 3 H), 7.63 (d, 1 H, J 8.0 Hz), 8.11 to 8.15 (m, 2 H), 9.74 (s, 1 H, CH=N), 11.90 (br. s, 1 H, NHIndole), 14.30 (br. s, H, NHTriazole); 13C-NMR (DMSO-d6, 100 MHz) δ 105.36, 111.93, 116.49, 116.71, 119.93, 121.29, 122.33, 123.76, 127.29, 128.58, 131.50, 131.59, 136.97, 143.43, 162.09, 163.66, 166.15; IR (cm−1): 1603, 2927, 3099, 3467; elemental analysis calculation for C17H12FN5S: C, 60.52; H, 3.59; F, 5.63; N, 20.76; S, 9.50 found: C, 60.26; H, 3.66; F, 5.71; N, 21.01; S, 9.55.
(E)-4-((3-Bromobenzylidene)amino)-5-(1H-indol-2-yl)-2,4-dihydro-3H-1,2,4-triazole-3-thione4. Yield: 49%; m.p. 236 to 237 °C, 1H-NMR (DMSO-d6, 400 MHz) δ 7.04 to 7.08 (m, 2 H), 7.22 (dd, 1H, J 7.5, J 8.2 Hz), 7.47 (d, 1 H, J 8.2 Hz), 7.58-7.67 (m, 2 H), 7.89 (d, 1 H, J 8.0 Hz), 8.06 (d, 1 H, J 7.8 Hz), 8.19 (s, 1 H), 9.80 (s, 1 H, CH=N), 11.91 (br. s, 1 H, NHIndol), 14.34 (br. s, H, NHTriazol); 13C-NMR (DMSO-d6, 100 MHz) δ 105.93, 112.43, 120.45, 121.81, 122.71, 122.96, 124.29, 127.76, 128.18, 131.80, 132.03, 134.75, 136.01, 137.48, 143.98, 162.60, 166.02; IR (cm−1): 1588, 2928, 3087, 3442; elemental analysis calculation for C17H12BrN5S: C, 51.27; H, 3.04; Br, 20.06; N, 17.58; S, 8.05. Found: C, 51.08; H, 3.22; Br, 20.13; N, 17.68; S, 8.11.
(E)-5-(1H-Indol-2-yl)-4-((4-methylbenzylidene)amino)-2,4-dihydro-3H-1,2,4-triazole-3-thione5. Yield: 45%; m.p. 225 to 226 °C, 1H-NMR (DMSO-d6, 300 MHz) δ 2.42 (s, 3 H, CH3), 6.99 to 7.05 (m, 2 H), 7.19 (dd, 1H, J 7.5, J 8.2 Hz), 7.42 to 7.45 (m, 3 H), 7.61 (d, 1 H, J 7.9 Hz), 7.91 (d, 2 H, J 7.9 Hz), 9.62 (s, 1 H, CH=N), 11.88 (br. s, 1 H, NHIndole), 14.25 (br. s, H, NHTriazole); 13C-NMR (DMSO-d6, 100 MHz) δ 21.8, 105.8, 112.4, 120.4, 121.7, 123.0, 124.2, 127.8, 129.4, 129.8, 130.4, 137.5, 143.9, 167.6; IR (cm−1): 1602, 2924, 3225, 3420 elemental analysis calculation for C18H15N5S: C, 64.84; H, 4.53; N, 21.01; S, 9.62. Found: C, 64.96; H, 4.67; N, 20.95; S, 9.39.
(E)-4-((2-Hydroxy-3-methoxybenzylidene)amino)-5-(1H-indol-2-yl)-2,4-dihydro-3H-1,2,4-triazole-3-thione6. Yield: 61%; m.p. 230 ot 231 °C, 1H-NMR (DMSO-d6, 500 MHz) δ 3.87 (s, 3 H, CH3), 7.03 to 7.07 (m, 3 H), 7.17 to 7.23 (m, 2 H), 7.45 (d, 1 H, J 8.4 Hz), 7.59 to 7.63 (m, 2 H), 9.88 (s, 1 H), 9.99 (s, 1 H, CH=N), 11.87 (br. s, 1 H, NHIndole), 14.23 (br. s, H, NHTriazole); 13C-NMR (DMSO-d6, 75 MHz) δ 56.14 (CH3), 105.23, 111.934, 115.78, 1168.52, 118.60, 119.69, 119.91, 121.27, 122.54, 123.69, 127.30, 136.93, 143.49, 148.37, 148.47, 162.07, 163.24; IR (cm−1): 1608, 2915, 3227, 3418; elemental analysis calculation for C18H15N5O2S: C, 59.17; H, 4.14; N, 8.76; S, 8.77 found: C, 59.43; H, 4.22; N, 18.97; S, 8.75.

3.2. General Procedure for the Synthesis of Indolo-Triazolo-Pyridazinethiones 7–16

To a mixture of indolyltriazolethione 1 (1.0 mmol) in ethanol (5.0 mL), the appropriate aldehyde (1.1 mmol) was added followed by the addition of 5 drops of concentrated HCl, and the mixture was refluxed for 1 to 2 h until a precipitate was formed. The solid product was cooled, filtered, dried, and recrystallized from ethanol.
5,6-Dihydro-14H-indolo[2,3-d]-6-phenyl-[1,2,4-triazolo][4,3-b]pyridazine-3(2H)thione7. Yield: 89%; m.p. >300 °C; 1H-NMR (DMSO-d6, 500 MHz) δ 5.92 (d, 1 H, J 5.7 Hz, H-6Pyridazine), 7.01 (d, 1 H, J 5.7 Hz, HNPyridazine, D2O exchangeable), 7.07 (dd, 1 H, J ≈ 7.5 Hz), 7.22 to 7.29 (m, 4 H), 7.41-7.48 (m, 4 H), 12.24 (br. s, 1 H, NHIndole, D2O exchangeable), 13.64 (br. s, 1 H, NHTriazole, D2O exchangeable); 13C-NMR (DMSO-d6, 125 MHz) δ 55.51 (C-6Pyridazine), 112.43, 116.79, 119.27, 119.74, 120.40, 124.08, 124.17, 127.065, 127.49, 128.25, 137.80, 139.91, 141.83, 164.21; IR (cm−1): 1628, 2897, 2985, 3067, 3162, 3222; HRMS (EI) calculated for C17H13N5S (M+): 319.0892. Found: 319.0902.
5,6-Dihydro-6-(4-flourophenyl)-14H-indolo[2,3-d]-[1,2,4-triazolo][4,3-b]pyridazine-3(2H)thione8. Yield: 80%; m.p. >300 °C; 1H-NMR (DMSO-d6, 300 MHz) δ 5.93 (d, 1 H, J 5.4 Hz, H-6Pyridazine), 7.04 (d, 1 H, J 5.4 Hz, HNPyridazine), 7.07 to 7.15 (m, 3 H), 7.26 (dd, 1 H, J 7.5, J 8.1 Hz), 7.40 to 7.48 (m, 4 H), 12.27 (br. s, 1H, NHIndole), 13.66 (br. s, 1 H, NHTriazole); 13C-NMR (DMSO-d6, 75 MHz) δ 54.81 (C-6Pyridazin), 112.51, 114.93, 115.21, 116.61, 119.34, 119.72, 120.54, 124.14, 124.19, 129.08, 129.19, 136.12, 137.83, 141.83, 163.14 (CPh), 164.32; IR (cm−1): 1604, 1632, 2907, 2960, 3068, 3265; HRMS (EI) calculated for C17H12N5SF (M+): 337.0797. Found: 337.0781.
6-(3-Bromophenyl)-5,6-dihydro-14H-indolo[2,3-d]-[1,2,4-triazolo][4,3-b]pyridazine-3(2H)thione9. Yield: 73%; m.p. >300 °C; 1H-NMR (DMSO-d6, 300 MHz) δ 5.99 (d, 1 H, J 5.1 Hz, H-6Pyridazine), 7.11 to 7.35 (m, 2 H), 7.43 (d, 1 H, J 8.1 Hz), 7.48 (d, 1 H, J 8.1 Hz), 7.59 (d, 1 H, J 7.8 Hz), 7.69 (s, 1 H,), 12.30 (br. s, 1H, NHIndole), 13.68 (br. s, 1 H, NHTriazole) 13C-NMR (DMSO-d6, 75 MHz) δ 55.10 (C-6Pyridazin), 113.05, 116.67, 119.80, 120.18, 121.17, 122.18, 124.65, 124.77, 126.48, 129.08, 130.19, 130.83, 130.98, 138.27, 142.27, 143.34, 164.93; IR (cm−1): 1627, 2906, 3075, 3202, 3263; HRMS (EI) calculated for C17H12N5SBr (M+): 396.9997. Found: 397.0000.
5,6-Dihydro-14H-indolo[2,3-d]-6-p-tolyl-5,6-[1,2,4-triazolo][4,3-b]pyridazine-3(2H)thione10. Yield: 91%; m.p. >300 °C; 1H-NMR (DMSO-d6, 300 MHz) δ 2.23 (s, 3 H, CH3), 5.84 (d, 1 H, J 5.8 Hz, H-6Pyridazine), 6.93 (d, 1 H, J 5.8 Hz, HNPyridazine), 7.04–7.28 (m, 6 H), 7.39 (d, 1 H, J 8.0 Hz), 7.46 (d, 1 H, J 8.2 Hz), 12.22 (br. s, 1H, NHIndole), 13.62 (br. s, 1 H, NHTriazole); 13C-NMR (DMSO-d6, 75 MHz) δ 20.62 (CH3), 55.44 (C-6Pyridazin), 112.45, 116.93, 119.34, 119.77, 120.39, 124.09, 124.18, 127.15, 128.84, 136.76, 136.85, 137.83, 141.89, 164.20; IR (cm−1): 1622, 3192, 3322; HRMS (EI) calculated for C18H15N5S (M+): 333.1048. Found: 333.1072.
5,6-Dihydro-14H-indolo[2,3-d]-6-(2,3,4-trimethoxyphenyl)-[1,2,4-triazolo][4,3-b]pyridazine-3(2H)thione11. Yield: 93%; m.p. 266 to 267 °C; 1H-NMR (DMSO-d6, 300 MHz) δ 3.72, 3.79, 3.96 (3s, 9 H, 3 OCH3), 5.99 (d, 1 H, J 7.1 Hz, H-6Pyridazine), 6.40 (d, 1 H, J 8.8 Hz), 6.63 (d, 1 H, J 8.8 Hz), 6.75 (d, 1 H, J 7.1 Hz, HNPyridazin), 6.97 (dd, 1 H, J 8.0, J 7.4 Hz), 7.05 (d, 1 H, J 8.0 Hz), 7.20 (dd, 1 H, J 7.4, J 8.3 Hz), 7.46 (d, 1 H, J 8.3 Hz), 12.26 (br. s, 1H, NHIndole), 13.63 (br. s, 1 H, NHTriazole); 13C-NMR (DMSO-d6, 100 MHz) δ 51.15, 55.70, 60.36, 61.57 (C-6Pyridazin, 3 OCH3), 107.41, 112.44, 115.44, 119.51, 120.18, 120.27, 122.96, 123.54, 124.06, 124.67, 137.94, 141.77, 141.89, 151.63, 153.42, 163.64; IR (cm−1): 1623, 3001, 3175; HRMS (EI) calculated for C20H19N5O3S (M+): 409.1209. Found: 409.1213.
6-(4-Chlorophenyl)-5,6-dihydro-14H-indolo[2,3-d]-[1,2,4-triazolo][4,3-b]pyridazine-3(2H)thione12. Yield: 68%; m.p. >300 °C; 1H-NMR (DMSO-d6, 300 MHz) δ 5.96 (d, 1 H, J 5.4 Hz, H-6Pyridazine), 7.08 to 7.14 (m, 2 H), 7.27 (dd, 1 H, J 7.5, J 8.1 Hz), 7.34 (d, 2 H, J 8.4 H), 7.41 (d, 2 H, J 8.4 H), 7.48 (d, 1 H, J 8.1 Hz), 7.53 (d, 1 H, J 7.8 Hz), 12.28 (br. s, 1H, NHIndole), 13.67 (br. s, 1 H, NHTriazole); 13C-NMR (DMSO-d6, 75 MHz) δ 54.69 (C-6Pyridazine), 112.53, 116.32, 119.36, 119.72, 120.60, 124.16, 124.23, 128.28, 128.94, 132.17, 137.82, 139.07, 141.80, 164.36; IR (cm−1): 1635, 2915, 3075, 3160, 3268; HRMS (EI) calculated for C17H12N5SCl (M+): 353.0502. Found: 353.0500.
6-(4-Bromophenyl)-5,6-dihydro-14H-indolo[2,3-d]-[1,2,4-triazolo][4,3-b]pyridazine-3(2H)thione13. Yield 71%; m.p. >300 °C; 1H-NMR (DMSO-d6, 300 MHz) δ 5.95 (d, 1 H, J 5.1 Hz, H-6Pyridazine), 7.10 to 7.55 (m, 9 H), 12.29 (br. s, 1H, NHIndole), 13.68 (br. s, 1 H, NHTriazole); 13C-NMR (DMSO-d6, 100 MHz) δ 54.75 (C-6Pyridazine), 112.55, 116.27, 119.39, 119.74, 120.63, 124.19, 124.26, 129.33, 131.22, 137.85, 139.54, 141.82, 164.38; IR (cm−1): 1629, 2907, 3071, 3202, 3268; HRMS (EI) calculated for C17H12N5SBr (M+): 396.9997. Found: 396.9964.
5,6-Dihydro-6-(3,4-dihydroxyphenyl)-14H-indolo[2,3-d]-[1,2,4-triazolo][4,3-b]pyridazine-3(2H)thione14. Yield 74%; m.p. >300 °C; 1H-NMR (DMSO-d6, 300 MHz) δ 5.66 (d, 1 H, J 6.3 Hz, H-6Pyridazine), 6.61 to 6.74 (m, 4 H), 7.03 (dd, 1 H, J 8.1 J 6.9 Hz), 7.20-7.25 (m, 2 H), 7.45 (d, 1 H, J 8.1 Hz), 8.78 (s, 1 H, OH), 8.87 (s, 1 H, OH), 12.18 (br. s, 1 H, NHIndole), 13.60 (br. s, 1 H, NHTriazole); 13C-NMR (DMSO-d6, 100 MHz) δ 55.89 (C-6Pyridazine), 112.38, 115.16, 115.23, 117.08, 118.60, 119.40, 119.90, 120.23, 124.01, 124.16, 130.42, 137.87, 141.86, 144.97, 145.01, 163.90; IR (cm−1): 1634, 2908, 3071, 3313; HRMS (EI) calculated for C17H13O2N5S (M+): 351.0790. Found: 351.0765.
5,6-Dihydro-6-(4-hydroxy-3-methoxyphenyl)-14H-indolo[2,3-d]-[1,2,4-triazolo][4,3-b]pyridazine-3(2H)thione15. Yield 87%; m.p. 300 to 301 °C; 1H-NMR (DMSO-d6, 300 MHz) δ 3.70 (s, 3 H, OCH3), 5.75 (d, 1 H, J 6.0 Hz, H-6Pyridazine), 6.57 to 6.64 (m, 2 H), 6.86 (d, 1 H, J 6.0 Hz), 7.07 (dd, 1 H, J 7.8, J 7.2 Hz), 7.21 to 7.28 (m, 2 H), 7.38 (d, 1 H, J 7.8 Hz), 7.45 (d, 1 H, J 8.1 Hz), 8.91 (s, 1 H, OH), 12.19 (br. s, 1H, NHIndole), 13.62 (br. s, 1 H, NHTriazole); 13C-NMR (DMSO-d6, 75 MHz) δ 55.53, 55.64 (C-6Pyridazine, OCH3), 111.49, 112.43, 115.15, 117.49, 119.25, 119.77, 119.82, 120.36, 124.04, 124.32, 130.40, 137.77, 141.98, 145.89, 147.37, 164.25; IR (cm−1): 1633, 2917, 3074, 3167, 3279, 3401; HRMS (EI) calculated for C18H15N5O2S (M+): 365.0946. Found: 365.0980.
5,6-Dihydro-6-(2-hydroxy-3-methoxyphenyl)-14H-indolo[2,3-d]-[1,2,4-triazolo][4,3-b]pyridazine-3(2H)thione16. Yield 89%; m.p. 200 to 201 °C; 1H-NMR (DMSO-d6, 500 MHz) δ 3.82 (s, 3 H, OCH3), 6.15 (d, 1 H, J 6.5 Hz, H-6Pyridazine), 6.27 (d, 1 H, J 7.6 Hz), 6.60 (dd, 1 H, J 7.9, J 8.0 Hz), 6.87 to 6.91 (m, 2 H), 6.96 (dd, 1 H, J 8.0, J 7.3 Hz), 7.10 (d, 1 H, J 8.0 Hz), 7.21 (dd, 1 H, J 7.3, J 8.3 Hz), 7.45 (d, 1 H, J 8.3 Hz), 9.27 (s, 1 H, OH), 12.24 (br. s, 1H, NHIndole), 13.68 (br. s, 1 H, NHTriazole); 13C-NMR (DMSO-d6, 125 MHz) δ 51.15 (C-6Pyridazin), 55.84 (OCH3), 111.51, 112.32, 115.64, 118.75, 119.54, 119.75, 119.87, 120.09, 123.71, 124.01, 125.72, 137.91, 141.15, 143.94, 147.54, 162.67; IR (cm−1): 1628, 2920, 3074, 3167, 3280, 3406; HRMS (FAB +ve) calculated for C18H16N5O2S (M+): 366.1025. Found: 366.091030.

3.3. General Procedure for the Alkylation with Di(bromomethyl)quinoxaline 19–25

The appropriate indolo-triazolo-pyridazinethiones (2.0 mmol) and K2CO3 (2.2 mmol) were stirred in acetone (10 mL) for 1 h; then, di(bromomethyl)quinoxaline (1.1 mmol) was added and stirring was continued overnight. The solvent was removed under vacuum, water was added, and the solid was obtained by filtration, dried, and recrystallized from dimethyl formamide (DMF).
2,3-Bis((5,6-Dihydro-14H-indolo[2,3-d]-6-phenyl-[1,2,4-triazolo][4,3-b]pyridazin-3-ylsulfanyl)methyl)quinoxaline19. Yield: 83%; m.p. 291 to 292 °C; 1H-NMR (DMSO-d6, 300 MHz) δ 5.04 (s, 4 H, 2 SCH2), 5.91 (d, 2 H, J 6.3 Hz, 2 H-6Pyridazine), 7.40 (dd, 2 H, J ≈ 7.5 Hz), 7.20 to 7.36 (m, 16 H), 7.47 (d, 2 H, J 8.1 Hz), 7.80 to 7.83 (m, 2 H), 8.00-8.03 (m, 2 H), 12.34 (br. s, 2 H, 2 NHIndole); 13C-NMR (DMSO-d6, 75 MHz) δ 35.86 (2 SCH2), 56.54 (2 C-6Pyridazine), 112.85, 114.53, 119.94, 120.71, 121.55, 123.92, 124.96, 127.73, 128.13, 128.71, 128.83, 130.74, 137.91, 140.29, 140.53, 146.53, 149.00, 151.10; IR (cm−1): 1611, 2926, 3143; elemental analysis calculated for C44H32N12S2: C, 66.65; H, 4.07; N, 21.20; S, 8.09. Found: C, 66.93; H, 4.15; N, 21.10; S, 8.15.
2,3-Bis((5,6-Dihydro-6-(4-flourophenyl)-14H-indolo[2,3-d]-[1,2,4-triazolo][4,3-b]pyridazin-3-ylsulfanyl)methyl)quinoxaline20. Yield: 87%; m.p. 294decomp. °C; 1H-NMR (DMSO-d6, 300 MHz) δ 5.045 (s, 4 H, 2 SCH2), 5.92 (d, 2 H, J 6.0 Hz, 2 H-6Pyridazine), 7.03 to 7.11 (m, 6 H), 7.22 (dd, 2 H, J 7.2, J 8.1 Hz), 7.29 to 7.38 (m, 8 H), 7.47 (d, 2 H, J 8.1 Hz), 7.80 to 7.83 (m, 2 H), 7.98 to 8.02 (m, 2 H), 12.36 (br. s, 2 H, 2 NHIndole); 13C-NMR (DMSO-d6, 75 MHz) δ 35.84 (2 SCH2), 55.92 (2 C-6Pyridazine), 112.89, 114.28, 119.87, 120.80, 121.60, 123.99, 124.88, 128.71, 129.75, 129.84, 130.74, 136.51, 137.92, 140.51, 146.47, 149.03, 151.10; IR (cm−1): 1608, 3060, 3147; HRMS (FAB +ve) calculated for C44H31N12S2F2 (M+): 829.2204. Found: 829.2220.
2,3-Bis((6-(3-Bromophenyl)-5,6-dihydro-14H-indolo[2,3-d]-[1,2,4-triazolo][4,3-b]pyridazin-3-ylsulfanyl)methyl)quinoxaline21. Yield: 79%; m.p. 298decomp. °C; 1H-NMR (DMSO-d6, 300 MHz) δ 5.05 (s, 4 H, 2 SCH2), 5.99 (d, 2 H, J 5.7 Hz, 2 H-6Pyridazine), 7.09 (dd, 2 H, J 7.8, J 7.5 Hz), 7.18 to 7.52 (m, 16 H), 7.80 to 7.83 (m, 2 H), 7.98 to 8.02 (m, 2 H), 12.39 (br. s, 2 H, 2 NHIndole); 13C-NMR (DMSO-d6, 75 MHz) δ 35.36 (2 SCH2), 55.22 (2 C-6Pyridazine), 112.44, 113.27, 119.34, 120.45, 121.06, 121.65, 123.60, 124.38, 128.23, 129.89, 130.24, 130.48, 130.60, 137.37, 140.00, 142.74, 145.87, 148.62, 150.53; IR (cm−1): 1609, 2924, 3058; HRMS (FAB +ve) calculated for C44H31N12S2Br2 (M+): 949.0603. Found: 949.0615.
2,3-Bis((5,6-Dihydro-14H-indolo[2,3-d]-6-p-tolyl-[1,2,4-triazolo][4,3-b]pyridazin-3-ylsulfanyl)methyl)quinoxaline22. Yield: 78%; m.p. 284 to 285 °C; 1H-NMR (DMSO-d6, 300 MHz) δ 2.18 (s, 6 H, 2 CH3), 5.02 (s, 4 H, 2 SCH2), 5.83 (d, 2 H, J 6.6 Hz, 2 H-6Pyridazine), 7.00 to 7.32 (m, 16 H), 7.46 (d, 2 H, J 8.4 Hz), 7.80 to 7.83 (m, 2 H), 7.99-8.01 (m, 2 H), 12.31 (br. s, 2 H, 2 NHIndole); 13C-NMR (DMSO-d6, 75 MHz) 21.08 (2 CH3), 35.79 (2 SCH2), 56.52 (2 C-6Pyridazine), 112.82, 114.67, 119.93, 120.65, 121.58, 123.88, 124.93, 127.75, 128.72, 129.36, 130.72, 137.20, 137.35, 137.91, 140.53, 146.56, 148.97, 151.14; IR (cm−1): 1610, 2917; HRMS (FAB +ve) calculated for C46H37N12S2 (M+): 821.2767. Found: 821.2767.
2,3-Bis((5,6-Dihydro-14H-indolo[2,3-d]-6-(2,3,4-trimethoxyphenyl)-[1,2,4-triazolo][4,3-b]pyridazin-3-ylsulfanyl)methyl)quinoxaline 23. Yield: 90%; m.p. 280 to 283 °C; 1H-NMR (DMSO-d6, 400 MHz) δ 3.71, 3.78, 3.92 (3s, 18 H, 6 OCH3), 4.98 (s, 4 H, 2 SCH2), 6.02 (d, 2 H, J 8.0 Hz, 2 H-6Pyridazine), 6.48 (d, 2 H, J 8.4 Hz), 6.64 (d, 2 H, J 8.4 Hz), 6.97 (br, 4 H), 7.11 (d, 2 H, J 8.4 Hz), 7.18 (br, 2 H), 7.45 (d, 2 H, J 8.0 Hz), 7.78 (br, 2 H), 7.93 (br, 2 H), 12.34 (br. s, 2 H, 2 NHIndole); 13C-NMR (DMSO-d6, 100 MHz) δ 35.15 (2 SCH2), 51.60, 55.71, 60.37, 61.51 (2 C-6Pyridazin, 6 OCH3), 107.61, 112.33, 113.40, 119.21, 119.98, 121.89, 123.07, 123.34, 123.81, 124.41, 128.17, 130.23, 137.57, 140.02, 141.87, 146.22, 148.23, 150.68, 151.58, 153.39; IR (cm−1): 1605, 2931, 3199; HRMS (FAB +ve) calculated for C50H45N12O6S2 (M+): 973.3026. Found: 973.3053.
2,3-Bis((6-(4-Chlorophenyl)-5,6-dihydro-14H-indolo[2,3-d]-[1,2,4-triazolo][4,3-b]pyridazin-3-ylsulfanyl)methyl)quinoxaline 24. Yield: 77%; m.p. 294decomp. °C; 1H-NMR (DMSO-d6, 300 MHz) δ 5.05 (s, 4 H, 2 SCH2), 5.95 (d, 2 H, J 6.0 Hz, 2 H-6Pyridazine), 7.07 (dd, 2 H, J 7.5 Hz), 7.20 to 7.48 (m, 16 H), 7.80 to 7.84 (m, 2 H), 7.98 to 8.01 (m, 2 H), 12.37 (br. s, 2 H, 2 NHIndol); 13C-NMR (DMSO-d6, 75 MHz) 35.81 (2 SCH2), 55.76 (2 C-6Pyridazine), 112.90, 113.98, 119.86, 120.85, 121.61, 124.90, 128.71, 128.84, 129.57, 130.75, 132.76, 137.91, 139.44, 140.50, 146.41, 149.06, 151.10; IR (cm−1): 1600, 2927, 3205; HRMS (FAB +ve) calculated for C44H31N12S2Cl2 (M+): 861.1613. Found: 861.1607.
2,3-Bis((6-(4-Bromophenyl)-5,6-dihydro-14H-indolo[2,3-d]-[1,2,4-triazolo][4,3-b]pyridazin-3-ylsulfanyl)methyl)quinoxaline25. Yield: 81%; m.p. 284 to 285 °C; 1H-NMR (DMSO-d6, 300 MHz) δ 5.05 (s, 4 H, 2 SCH2), 5.94 (d, 2 H, J 5.7 Hz, 2 H-6Pyridazine), 7.08 (dd, 2 H, J7.5 Hz), 7.21 to 7.49 (m, 16 H), 7.80 to 7.84 (m, 2 H), 7.98 to 8.01 (m, 2 H), 12.37 (br. s, 2 H, 2 NHIndole); 13C-NMR (DMSO-d6, 75 MHz) 35.82 (2 SCH2), 55.80 (2 C-6Pyridazin), 112.91, 113.92, 119.86, 120.86, 121.35, 124.04, 124.91, 128.71, 129.93, 130.74, 131.77, 137.92, 139.88, 140.51, 146.41, 149.08, 151.09; IR (cm−1): 1602, 2925, 3198; HRMS (FAB +ve) calculated for C44H31N12S2Br2 (M+): 949.0603. Found: 949.0669.

4. Conclusions

A fascinating cyclization reaction approach was achieved when 4-amino-5-(1H-indol-2-yl)-2,4-dihydro-3H-1,2,4-triazole-3-thione 1 was reacted with ten aromatic aldehydes in ethanol and concentrated HCl to obtain indolo-triazolo-pyridazinethiones 7–16 in an excellent yield. Moreover, the alkylation of indolo-triazolo-pyridazinethiones 7–13 with 2,3-bis(bromomethyl)quinoxaline as a linker in acetone and K2CO3 afforded 2,3-bis((5,6-dihydro-14H-indolo[2,3-d]-6-aryl-[1,2,4-triazolo][4,3-b]pyridazin-3 ylsulfanyl)methyl)quinoxalines 19–25 in a high yield. Studies to establish their applications are in progress.

Supplementary Materials

NMR spectra (Figures S1–S44); and IR analyses (Figures S45–S60) associated with this article can be found in the online version.

Author Contributions

Conceptualization, A.T.A.B.; Data curation, A.A.M.S.; Formal analysis, S.Y. and A.B.; Funding acquisition, A.B.; Methodology, A.T.A.B.; Software, S.Y.; Supervision, A.T.A.B.; Validation, A.A.M.S.; Visualization, A.B.; Writing—Original draft, A.T.A.B.; Writing—Review and editing, A.B. All authors have read and agreed to the published version of the manuscript.

Funding

The authors would like to extend their sincere appreciation to the Researchers Supporting project number (RSP-2019/64), King Saud University, Riyadh, Saudi Arabia.

Acknowledgments

The authors would like to extend their sincere appreciation to the Researchers Supporting project number (RSP-2019/64), King Saud University, Riyadh, Saudi Arabia.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Kumari, A.; Singh, R.K. Medicinal chemistry of indole derivatives: Current to future therapeutic prospectives. Bioorg. Chem. 2019, 89, 103021. [Google Scholar] [CrossRef] [PubMed]
  2. Kharb, R.; Sharma, P.C.; Yar, M.S. Pharmacological significance of triazole scaffold. J. Enzyme Inhib. Med. Chem. 2011, 26, 1–21. [Google Scholar] [CrossRef] [PubMed]
  3. Kashyap, A.; Silakari, O. Triazoles: Multidimensional 5-membered nucleus for designing multitargeting agents. In Key Heterocycle Cores for Designing Multitargeting Molecules; Elsevier: Amsterdam, The Netherlands, 2018; pp. 323–342. [Google Scholar]
  4. Maftei, C.V.; Fodor, E.; Jones, P.G.; Daniliuc, C.G.; Franz, M.H.; Kelter, G.; Fiebig, H.-H.; Tamm, M.; Neda, I. Novel 1,2,4-oxadiazoles and trifluoromethylpyridines related to natural products: Synthesis, structural analysis and investigation of their antitumor activity. Tetrahedron 2016, 72, 1185–1199. [Google Scholar] [CrossRef]
  5. Neda, I.; Kaukorat, T.; Schmutzler, R.; Niemeyer, U.; Kutscher, B.; Pohl, J.; Engel, J. Benzodiaza-, Benzoxaza- and benzodioxaphosphorinones- formation, reactivity, structure and biological activity. Phosphorus Sulfur Silicon 2000, 162, 81–218. [Google Scholar] [CrossRef]
  6. Simon, M.; Csunderlik, C.; Cotarca, L.; Caproiu, M.T.; Neda, I.; Turoczi, M.C.; Volpicelli, R. Synthesis of new active 0-nitrophenyl carbamates. Synth. Comun. 2005, 35, 1471–1479. [Google Scholar] [CrossRef]
  7. Mohammad, Y.; Fazili, K.M.; Bhat, K.A.; Ara, T. Synthesis and biological evaluation of novel 3-O-tethered triazoles of diosgenin as potent antiproliferative agents. Steroids 2017, 118, 1–8. [Google Scholar]
  8. Huang, M.; Deng, Z.; Tian, J.; Liu, T. Synthesis and biological evaluation of salinomycin triazole analogues as anticancer agents. Eur. J. Med. Chem. 2017, 127, 900–908. [Google Scholar] [CrossRef]
  9. Gujjar, R.; Marwaha, A.; El Mazouni, F.; White, J.; White, K.L.; Creason, S.; Shackleford, D.M.; Baldwin, J.; Charman, W.N.; Buckner, F.S.; et al. Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice. J. Med. Chem. 2009, 52, 1864–1872. [Google Scholar] [CrossRef] [Green Version]
  10. Chen, M.; Lu, S.; Yuan, G.; Yang, S.; Du, X. Synthesis and antibacterial activity of some heterocyclic β-enamino ester derivatives with 1, 2, 3-triazole. Heterocycl. Commun. 2000, 6, 421–426. [Google Scholar] [CrossRef]
  11. Ayati, A.; Emami, S.; Foroumadi, A. The importance of triazole scaffold in the development of anticonvulsant agents. Eur. J. Med. Chem. 2016, 109, 380–392. [Google Scholar] [CrossRef] [Green Version]
  12. Akhtar, T.; Hameed, S.; Khan, K.M.; Choudhary, M.I. Syntheses, urease inhibition, and antimicrobial studies of some chiral 3-substituted-4-amino-5-thioxo-1H, 4H-1,2,4-triazoles. Med. Chem. 2008, 4, 539–543. [Google Scholar] [CrossRef]
  13. Sevaille, L.; Gavara, L.; Bebrone, C.; De Luca, F.; Nauton, L.; Achard, M.; Mercuri, P.; Tanfoni, S.; Borgianni, L.; Guyon, C.; et al. 1,2,4-Triazole-3-thione compounds as inhibitors of dizinc metallo-β-lactamases. ChemMedChem 2017, 12, 972–985. [Google Scholar] [CrossRef]
  14. Gilmore, J.L.; King, B.W.; Asakawa, N.; Harrison, K.; Tebben, A.; Sheppeck, J.E., II; Liu, R.Q.; Covington, M.; Duan, J.J.W. Synthesis and structure–activity relationship of a novel, non-hydroxamate series of TNF-α converting enzyme inhibitors. Bioorg. Med. Chem. Lett. 2007, 17, 4678–4682. [Google Scholar] [CrossRef] [PubMed]
  15. Maingot, L.; Leroux, F.; Landry, V.; Dumont, J.; Nagase, H.; Villoutreix, B.; Sperandio, O.; Deprez-Poulain, R.; Deprez, B. New non-hydroxamic ADAMTS-5 inhibitors based on the 1,2,4-triazole-3-thiol scaffold. Bioorg. Med. Chem. Lett. 2010, 20, 6213–6216. [Google Scholar] [CrossRef] [PubMed]
  16. Kruse, L.I.; Kaiser, C.; DeWolf, W.E.; Finkelstein, J.A.; Frazee, J.S.; Hilbert, E.L.; Ross, S.T.; Flaim, K.E.; Sawyer, J.L. Some benzyl-substituted imidazoles, triazoles, tetrazoles, pyridinethiones, and structural relatives as multisubstrate inhibitors of dopamine. β-hydroxylase. 4. Structure-activity relationships at the copper binding site. J. Med. Chem. 1990, 33, 781–789. [Google Scholar] [CrossRef] [PubMed]
  17. Timur, İ.; Kocyigit, Ü.M.; Dastan, T.; Sandal, S.; Ceribası, A.O.; Taslimi, P.; Gulcin, İ.; Koparir, M.; Karatepe, M.; Çiftçi, M. In vitro cytotoxic and in vivo antitumoral activities of some aminomethyl derivatives of 2, 4-dihydro-3H-1,2,4-triazole-3-thiones—Evaluation of their acetylcholinesterase and carbonic anhydrase enzymes inhibition profiles. J. Biochem. Mol. Toxic. 2019, 33, e22239. [Google Scholar] [CrossRef] [Green Version]
  18. Hamdy, R.; Ziedan, N.; Ali, S.; El-Sadek, M.; Lashin, E.; Brancale, A.; Jones, A.T.; Westwell, A.D. Synthesis and evaluation of 3-(benzylthio)-5-(1H-indol-3-yl)-1,2,4-triazol-4-amines as Bcl-2 inhibitory anticancer agents. Bioorg. Med. Chem. Lett. 2013, 23, 2391–2394. [Google Scholar] [CrossRef]
  19. Ziedan, N.I.; Hamdy, R.; Cavaliere, A.; Kourti, M.; Prencipe, F.; Brancale, A.; Jones, A.T.; Westwell, A.D. Virtual screening, SAR, and discovery of 5-(indole-3-yl)-2-[(2-nitrophenyl) amino][1,3,4]-oxadiazole as a novel Bcl-2 inhibitor. Chem. Biol. Drug Des. 2017, 90, 147–155. [Google Scholar] [CrossRef]
  20. Boraei, A.T.; Ghabbour, H.A.; Gomaa, M.S.; El Ashry, E.S.H.; Barakat, A. Synthesis and anti-proliferative assessment of triazolo-thiadiazepine and triazolo-thiadiazine scaffolds. Molecules 2019, 24, 4471. [Google Scholar] [CrossRef] [Green Version]
  21. Boraei, A.T.A.; Gomaa, M.S.; El Sayed, E.S.H.; Duerkop, A. Design, selective alkylation and X-ray crystal structure determination of dihydro-indolyl-1,2,4-triazole-3-thione and its 3-benzylsulfanyl analogue as potent anticancer agents. Eur. J. Med. Chem. 2017, 125, 360–371. [Google Scholar] [CrossRef]
  22. Darestani-Farahani, M.; Faridbod, F.; Ganjali, M.R. A sensitive fluorometric DNA nanobiosensor based on a new fluorophore for tumor suppressor gene detection. Talanta 2018, 190, 140–146. [Google Scholar] [CrossRef]
  23. Shi, Z.; Zhao, Z. Microwave irradiation synthesis of novel indole triazole Schiff base fluorescent probe for Al3+ ion. Inorganica Chim. Acta 2019, 498, 119135. [Google Scholar] [CrossRef]
  24. Boraei, A.T.; Singh, P.K.; Sechi, M.; Satta, S. Discovery of novel functionalized 1, 2, 4-triazoles as PARP-1 inhibitors in breast cancer: Design, synthesis and antitumor activity evaluation. Eur. J. Med. Chem. 2019, 182, 111621. [Google Scholar] [CrossRef] [PubMed]
  25. Boraei, A.T.; Ashour, H.K.; El Sayed, H.; Abdelmoaty, N.; El-Falouji, A.I.; Gomaa, M.S. Design and synthesis of new phthalazine-based derivatives as potential EGFR inhibitors for the treatment of hepatocellular carcinoma. Bioorg. Chem. 2019, 85, 293–307. [Google Scholar] [CrossRef]
  26. Chehrouri, M.; Othman, A.A.; Jiménez-Cecilia, S.; Moreno-Cabrerizo, C.; Sansano, J.M. 4-Amino-3-pentadecyl-3H-1,2,4-triazole-3-thiones and 3-pentadecyl-1,3,4-oxadiazole-2 (3H)-thione for the preparation of dimeric palladium (II) complexes and their applications in Tsuji–Trost and Mizoroki–Heck reactions. Synth. Commun. 2019, 49, 1301–1307. [Google Scholar] [CrossRef]
  27. Abdallah, M.A.; Riyadh, S.M.; Abbas, I.M.; Gomha, S.M. Synthesis and biological activities of 7-arylazo-7H-pyrazolo [5,1-c][1,2,4] triazol-6 (5H)-ones and 7-arylhydrazono-7H-[1,2,4] triazolo [3,4-b][1,3,4] thiadiazines. J. Chin. Chem. Soc. 2005, 52, 987–994. [Google Scholar] [CrossRef]
  28. Gomha, S.M.; Riyadh, S.M. Synthesis under microwave irradiation of [1,2,4] triazolo [3,4-b][1,3,4] thiadiazoles and other diazoles bearing indole moieties and their antimicrobial evaluation. Molecules 2011, 16, 8244–8256. [Google Scholar] [CrossRef]
  29. Peng, Y.; Zhao, Z.; Liu, X.; Li, G. Microwave-assisted synthesis and biological activity of new Schiff bases derived from dimers of 4-amino-3-[3-(1-benzyl)indole]-5-thiomethyl-1,2,4-triazole. Res. Chem. Intermediat. 2013, 39, 1897–1905. [Google Scholar] [CrossRef]
  30. Peng, Y.L.; Liu, X.L.; Wang, X.H.; Zhao, Z.G. Microwave-assisted synthesis and antibacterial activity of derivatives of 3-[1-(4-fluorobenzyl)-1H-indol-3-yl]-5-(4-fluorobenzylthio)-4H-1, 2, 4-triazol-4-amine. Chem. Pap. 2014, 68, 401–408. [Google Scholar] [CrossRef]
  31. Shi, Z.; Zhao, Z.; Huang, M.; Fu, X. Ultrasound-assisted, one-pot, three-component synthesis and antibacterial activities of novel indole derivatives containing 1,3,4-oxadiazole and 1,2,4-triazole moieties. C. R. Chim. 2015, 18, 1320–1327. [Google Scholar] [CrossRef]
  32. Cascioferro, S.; Parrino, B.; Li Petri, G.; Cusumano, M.G.; Schillaci, D.; Sarno, V.D.; Musella, S.; Giovannetti, E.; Cirrincione, G.; Diana, P. 2,6-Disubstituted imidazo[2,1-b][1,3,4]thiadiazole derivatives as potent staphylococcal biofilm inhibitors. Eur. J. Med. Chem. 2019, 167, 200–210. [Google Scholar] [CrossRef]
  33. Ishikawa, H.; Sugiyama, T.; Kurita, K.; Yokoyama, A. Synthesis and antimicrobial activity of 2, 3-bis (bromomethyl) quinoxaline derivatives. Bioorg. Chem. 2012, 41, 1–5. [Google Scholar] [CrossRef] [PubMed]
  34. Parrino, B.; Carbone, A.; Spanò, V.; Montalbano, A.; Giallombardo, D.; Barraja, P.; Attanzio, A.; Tesoriere, L.; Sissi, C.; Palumbo, M.; et al. Aza-isoindolo and isoindolo-azaquinoxaline derivatives with antiproliferative activity. Eur. J. Med. Chem. 2015, 94, 367–377. [Google Scholar] [CrossRef] [PubMed]
  35. Parrino, B.; Carbone, A.; Ciancimino, C.; Spanò, V.; Montalbano, A.; Barraja, P.; Cirrincione, G.; Diana, P.; Sissi, C.; Palumbo, M.; et al. Water-soluble isoindolo[2,1-a]quinoxalin-6-imines: In vitro antiproliferative activity and molecular mechanism(s) of action. Eur. J. Med. Chem. 2015, 94, 149–162. [Google Scholar] [CrossRef] [PubMed]
  36. Bruker, A. SAINT Software Reference Manual; Bruker AXS, Inc.: Madison, WI, USA, 1998. [Google Scholar]
  37. Spek, L.A. Single-crystal structure validation with the program PLATON. J. Appl. Chem. 2002, 36, 7–13. [Google Scholar]
  38. Sheldrick, G.M. Crystal structure refinement with SHELXL. Acta Cryst. C. 2015, 71, 3–8. [Google Scholar] [CrossRef] [PubMed]
Sample Availability: Samples of the compounds 2–16 and 19–25 are available from the authors.
Molecules 25 00450 g001 550
Figure 1. Selected 1,2,4-triazole- indole scaffolds.
Figure 1. Selected 1,2,4-triazole- indole scaffolds.
Molecules 25 00450 g001
Molecules 25 00450 sch001 550
Scheme 1. Synthesis of Schiff bases 2–6 and cyclized indolo-triazolo-pyridazinethiones 7–16.
Scheme 1. Synthesis of Schiff bases 2–6 and cyclized indolo-triazolo-pyridazinethiones 7–16.
Molecules 25 00450 sch001
Molecules 25 00450 sch002 550
Scheme 2. Coupling of indolo-triazolo-pyridazinethiones 7–13 with 2,3-bis(bromomethyl)quinoxaline.
Scheme 2. Coupling of indolo-triazolo-pyridazinethiones 7–13 with 2,3-bis(bromomethyl)quinoxaline.
Molecules 25 00450 sch002
Molecules 25 00450 g002 550
Figure 2. (A) 1H nuclear magnetic resonance (NMR) of 2, (B) 13C-NMR of 2, (C) 1H-NMR of 7, and (D) 13C-NMR of 7.
Figure 2. (A) 1H nuclear magnetic resonance (NMR) of 2, (B) 13C-NMR of 2, (C) 1H-NMR of 7, and (D) 13C-NMR of 7.
Molecules 25 00450 g002
Molecules 25 00450 g003 550
Figure 3. Structure and atom numbering of 6.
Figure 3. Structure and atom numbering of 6.
Molecules 25 00450 g003
Molecules 25 00450 g004 550
Figure 4. The molecular packing of the synthesized compound 6. Intra and intermolecular hydrogen bonds are indicated as dashed lines.
Figure 4. The molecular packing of the synthesized compound 6. Intra and intermolecular hydrogen bonds are indicated as dashed lines.
Molecules 25 00450 g004
Table
Table 1. Crystal data for 6.
Table 1. Crystal data for 6.
Chemical formulaC38H26N10O4S2
Formula weight726.79 g/mol
Temperature104(2) K
Wavelength1.54178 Å
Crystal size0.030 × 0.070 × 0.130 mm
Crystal habitYellow plate
Crystal systemTriclinic
Space groupP -1
Unit cell dimensionsa = 10.1105(6) Å
b = 13.1764(6) Å
c = 14.2858(6) Å
Volume1705.44(15) Å3
Z2
Density (calculated)1.415 g/cm3
Absorption coefficient1.893 mm−1
F(000)752
Table
Table 2. Data collection and structure refinement for 6. (RMS, root mean square)
Table 2. Data collection and structure refinement for 6. (RMS, root mean square)
Theta range for data collection3.38 to 68.23°
Index ranges−12 ≤ h ≤ 12, −15 ≤ k ≤ 15, −17 ≤ l ≤ 17
Reflections collected54525
Independent reflections6232 [R(int) = 0.1173]
Coverage of independent reflections99.9%
Absorption correctionMulti-scan
Max. and min. transmission0.9470 and 0.7960
Structure solution techniquedirect methods
Structure solution programSHELXT 2014/5 (Sheldrick, 2014)
Refinement methodFull-matrix least-squares on F2
Refinement programSHELXL-2017/1 (Sheldrick, 2017)
Function minimizedΣ w(Fo2 − Fc2)2
Data/restraints/parameters6232/0/471
Goodness-of-fit on F21.085
Final R indices4104 data;
I > 2σ(I)
all data
Weighting schemew = 1/[σ2(Fo2) + (0.1000P)2]
where P = (Fo2 + 2Fc2)/3
Largest diff. peak and hole1.57 and −0.52 eÅ−3
RMS deviation from mean0.110 eÅ−3
Table
Table 3. Hydrogen bond parameters for 6.
Table 3. Hydrogen bond parameters for 6.
D-H…AD-HH…AD…AD-H…A
O1-H1…N10.841.942.659(6)143
O3-H3A…N60.841.952.664(6)143
C11-H11…S20.952.513.391(5)154

Share and Cite

MDPI and ACS Style

Boraei, A.T.A.; Sarhan, A.A.M.; Yousuf, S.; Barakat, A. Synthesis of a New Series of Nitrogen/Sulfur Heterocycles by Linking Four Rings: Indole; 1,2,4-Triazole; Pyridazine; and Quinoxaline. Molecules 2020, 25, 450. https://doi.org/10.3390/molecules25030450

AMA Style

Boraei ATA, Sarhan AAM, Yousuf S, Barakat A. Synthesis of a New Series of Nitrogen/Sulfur Heterocycles by Linking Four Rings: Indole; 1,2,4-Triazole; Pyridazine; and Quinoxaline. Molecules. 2020; 25(3):450. https://doi.org/10.3390/molecules25030450

Chicago/Turabian Style

Boraei, Ahmed T. A., Ahmed A. M. Sarhan, Sammer Yousuf, and Assem Barakat. 2020. "Synthesis of a New Series of Nitrogen/Sulfur Heterocycles by Linking Four Rings: Indole; 1,2,4-Triazole; Pyridazine; and Quinoxaline" Molecules 25, no. 3: 450. https://doi.org/10.3390/molecules25030450

APA Style

Boraei, A. T. A., Sarhan, A. A. M., Yousuf, S., & Barakat, A. (2020). Synthesis of a New Series of Nitrogen/Sulfur Heterocycles by Linking Four Rings: Indole; 1,2,4-Triazole; Pyridazine; and Quinoxaline. Molecules, 25(3), 450. https://doi.org/10.3390/molecules25030450

Article Metrics

Back to TopTop